Welcome to our dedicated page for LakeShore Biopharma Co. SEC filings (Ticker: LSBCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is dedicated to the SEC-related disclosure activity of LakeShore Biopharma Co., Ltd (LSBCF), previously known as YS Biopharma. While no individual SEC filings are listed here, the company has stated in its public announcements that it remains a reporting company with the U.S. Securities and Exchange Commission and that it will use SEC filings to communicate key corporate events.
In connection with its transition from The Nasdaq Capital Market to the OTC Pink Open Market, LakeShore Biopharma indicated that it continues to file reports with the SEC. The company also announced that, following a Nasdaq delisting determination based on minimum bid price requirements and prior reverse stock split history, its ordinary shares and warrants began trading on the OTC Pink Open Market under LSBCF and LSBWF. These developments are typically reflected in current reports and other regulatory submissions.
For its going‑private transaction, LakeShore Biopharma has stated that it will furnish a current report on Form 6‑K to the SEC that will include the Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. as an exhibit. The company also plans to prepare and mail a proxy statement to shareholders and to file a Schedule 13E‑3 transaction statement with the SEC, which will include the proxy statement. These documents are intended to provide detailed information about the merger terms, shareholder voting, and the company’s transition to private ownership.
On Stock Titan, users can monitor when such filings are made available through the SEC’s EDGAR system and use AI-powered tools to obtain simplified explanations of complex documents such as Form 6‑K, proxy statements, and Schedule 13E‑3, helping them understand how LakeShore Biopharma describes its corporate actions and governance changes.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.
LakeShore Biopharma reported that its board’s special committee has received a revised, preliminary and non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares they do not already own for US$0.06 per share in cash.
The bidders referenced arbitral awards totaling approximately RMB576.5 million against certain PRC subsidiaries, which they believe constitute a “Company Material Adverse Effect” under the existing November 2025 merger agreement and give them the right not to close on current terms. The special committee will evaluate the lower-priced offer, and the company stresses there is no assurance any definitive offer, agreement, or transaction will ultimately be completed.
LakeShore Biopharma’s controlling shareholder group filed Amendment No. 5 to its Schedule 13D, outlining a sharply revised going‑private proposal. The consortium now proposes to buy all publicly held ordinary shares at US$0.06 per share, compared with the prior US$0.90 offer, via equity funding and rollover of existing holdings.
The filing cites arbitral awards imposing approximately RMB576.5 million of monetary liabilities and related litigation uncertainty as key reasons for the lower price, warning these could materially weaken the company’s financial condition. If completed, the merger would take LakeShore private, terminate SEC registration and remove its shares from the OTC Pink market. The proposal remains non‑binding, with no assurance that definitive agreements or a transaction will be consummated.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.